(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 89.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Agios Pharmaceuticals's revenue in 2024 is $26,823,000.On average, 5 Wall Street analysts forecast AGIO's revenue for 2024 to be $4,575,834,002, with the lowest AGIO revenue forecast at $1,713,942,834, and the highest AGIO revenue forecast at $13,159,709,270. On average, 5 Wall Street analysts forecast AGIO's revenue for 2025 to be $5,329,069,731, with the lowest AGIO revenue forecast at $3,675,142,994, and the highest AGIO revenue forecast at $9,033,883,604.
In 2026, AGIO is forecast to generate $11,066,114,051 in revenue, with the lowest revenue forecast at $6,816,434,941 and the highest revenue forecast at $19,452,408,238.